Antibodies against CD24
Anti-CD24 antibodies with O-glycosylation-dependent binding to TF antigen on cancer cells address the issue of non-specific binding, improving safety in cancer therapy by targeting tumor-specific CD24 and reducing normal tissue interaction.
WO2026130747A1 Publication Date: 2026-06-25PENTIXAPHARM AG
4 Cites 0 Cited by
Patent Information
- Application Number
- PCT/EP2025/057633
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-19
- Filing Date
- 2025-03-20
- Publication Date
- 2026-06-25
AI Technical Summary
Technical Problem
Existing anti-CD24 antibodies lack the ability to distinguish between CD24 on cancer cells and normal tissue, leading to potential adverse effects due to non-specific binding.
Method used
Development of anti-CD24 antibodies that specifically bind to tumor-associated CD24 in an O-glycosylation-dependent manner, targeting the Thomsen-Friedenreich antigen (TF; Gaipi-3GalNAca1-) present on cancer cells, while avoiding sialylated Thomsen-Friedenreich antigen (sTF) on normal cells.
Benefits of technology
The antibodies exhibit enhanced tumor specificity, reducing adverse effects by preferentially binding to CD24 on cancer cells and minimizing interaction with normal tissues, thus enhancing safety in cancer immunotherapy.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention pertains to anti-CD24 antibodies which bind CD24 in an O-glycosylation-dependent manner. Thereby, the antibodies are specific for tumor-associated CD24. The invention further provides pharmaceutical compositions containing said anti-CD24 antibodies and their use in cancer treatment.
Need to check novelty before this filing date? Find Prior Art